Sotera Health Company (SHC) Barclays 28th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Barclays 28th Annual Global Healthcare Conference summary
11 Mar, 2026Energy and supply chain management
Utility and gas costs are largely fixed under long-term contracts, minimizing risk from energy price fluctuations.
Ethylene oxide gas supply is secured with fixed contracts, especially in the U.S., reducing exposure to market volatility.
No current supply chain constraints are reported.
Financial performance and outlook
Achieved over 5% top-line and 8% bottom-line growth in 2025, with $200M+ in free cash flow and 118 basis points of margin expansion.
Deleveraged and repriced debt, with private equity sponsors reducing their stake to about 12%.
Projected 5%-6.5% revenue growth and 5.5%-7% EBITDA growth for 2026.
20 consecutive years of growth, maintaining 50%+ EBITDA margins.
Demand, seasonality, and customer dynamics
First quarter is typically the softest due to customer and facility cycles, not due to pull-forward or inventory stuffing.
Demand visibility is strong, with 40%-45% of annual business expected in the first half of the year.
No material changes in customer order dynamics or inventory management; volumes remain stable.
Healthcare utilization remains elevated, with several weeks to months of advance planning for orders.
Latest events from Sotera Health Company
- 2026 guidance targets 5%-6.5% growth, with strong momentum and disciplined capital allocation.SHC
2026 KeyBanc Capital Markets Healthcare Forum20 Mar 2026 - 2025 saw record revenue and margin growth, with 2026 guidance projecting further gains.SHC
Q4 202524 Feb 2026 - Targeting 5%-7% annual growth and $500M+ free cash flow, driven by strategic market focus.SHC
Investor Day 20243 Feb 2026 - Q3 2024 saw 8.5% revenue growth, margin expansion, and improved leverage amid strong liquidity.SHC
Q3 20243 Feb 2026 - Q2 net revenues up 8.3%, EBITDA up 7%, but net income fell on refinancing and interest costs.SHC
Q2 20242 Feb 2026 - Volume recovery, regulatory compliance, and CapEx discipline support growth and margin rebound.SHC
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Surpassed $1.16B revenue in 2025, with strong growth, margins, and strategic execution.SHC
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Three-year targets set for 5%-7% revenue growth and $500-$600M free cash flow, driven by global scale.SHC
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q1 2025 saw revenue and margin growth, but net loss from EO litigation settlement.SHC
Q1 202527 Dec 2025